Evotec AG (NASDAQ:EVTC) will issue its Q214 quarterly earnings data on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.40 per share and revenue of $94.40 million for the quarter.
Evotec AG (NASDAQ:EVTC) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.39 by $0.01. The company had revenue of $87.20 million for the quarter, compared to the consensus estimate of $91.26 million. The company’s quarterly revenue was down .1% on a year-over-year basis. On average, analysts expect Evotec AG to post $1.68 EPS for the current fiscal year and $1.84 EPS for the next fiscal year.
Shares of Evotec AG (NASDAQ:EVTC) traded down 0.31% on Tuesday, hitting $22.28. 242,557 shares of the company’s stock traded hands. Evotec AG has a 1-year low of $20.64 and a 1-year high of $26.33. The stock has a 50-day moving average of $23.57 and a 200-day moving average of $23.99. The company’s market cap is $1.746 billion.
On the ratings front, analysts at Goldman Sachs initiated coverage on shares of Evotec AG in a research note on Tuesday, July 8th. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $26.50.
Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.